Format

Send to

Choose Destination
Allergy. 2017 Feb;72(2):291-299. doi: 10.1111/all.12993. Epub 2016 Aug 24.

Ten-year trends in direct costs of asthma: a population-based study.

Author information

1
Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada.
2
Centre for Clinical Epidemiology and Evaluation, The University of British Columbia, Vancouver, BC, Canada.
3
Department of Medicine, Institute for Heart and Lung Health, The University of British Columbia, Vancouver, BC, Canada.
4
The Institute for Clinical Evaluative Sciences, Toronto, ON, Canada.
5
The Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada.
6
The Hospital for Sick Children, Toronto, ON, Canada.
7
Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
8
School of Pharmacy, Memorial University of Newfoundland, St. John's, NF, Canada.

Abstract

INTRODUCTION:

There is little information on recent trends in the economic burden of asthma. Our objective was to estimate the excess costs of asthma and their trend in British Columbia, Canada, from 2002 to 2011.

METHODS:

A retrospective cohort of individuals aged 5-55 years was constructed from the provincial administrative health databases, consisting of patients with physician-diagnosed asthma and a propensity-score-matched comparison sample from the general population. Total direct medical costs were calculated as the sum of hospitalizations, outpatient visits and medication costs, adjusted to 2012 Canadian dollars ($). Excess costs were defined as the difference in costs between the asthma and comparison groups.

RESULTS:

A total of 341 457 individuals (mean age at entry 27.3, 54.1% female) were equally divided into the asthma and comparison groups. Excess costs in patients with asthma were $1028.0 (95% CI $982.7-$1073.4) per patient-year (PY). Medications contributed to the greatest share of excess costs ($471.7/PY), whereas hospitalization and outpatient costs were, respectively, $272.2/PY and $284.1/PY. Only $192.9/PY was attributable to asthma itself. There was a 2.9%/year increase in excess costs (P < 0.001), a combination of asthma-attributable costs declining by 0.8%/year while nonasthma excess costs increasing by 3.8%/year. The most dramatic trend was observed in asthma-related outpatient costs, which decreased by %6.6/year.

CONCLUSIONS:

A significant share of excess costs in asthma is not attributable to the disease itself. The pattern of costs changed significantly during the study period. The burden of comorbid conditions should be considered in developing evidence-based policies for management of patients with asthma.

KEYWORDS:

asthma; burden of diseases; cohort studies; costs; observational studies

PMID:
27455382
DOI:
10.1111/all.12993
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center